Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can zapping the brain boost speech therapy for aphasia patients?

NCT ID NCT06921265

Symptom relief Sponsor: IRCCS San Raffaele Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding a non-invasive brain stimulation technique called transcranial magnetic stimulation (TMS) to speech therapy can improve language skills in people with primary progressive aphasia (PPA), a condition that slowly damages language areas of the brain. About 75 participants (45 with PPA and 30 healthy controls) will receive either speech therapy alone or speech therapy plus TMS. The goal is to see if the combination leads to better naming and communication, and whether personalized TMS works better than a standard approach.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 75 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

May 2026

An estimate. Start dates often move.

Expected to finish

Apr 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 85 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria for patients * Clinical and imaging-supported diagnosis of any variant of PPA (svPPA, lvPPA, nfvPPA) according to international diagnostic criteria (Gorno- Tempini et al., 2011) * Age range: 40-85 * MMSE\>15 * Native Italian Speaker * Right handedness * Stable pharmacological treatment of at least 4 weeks and without any change during the observation period (48 weeks) * Oral and written informed consent to study participation Exclusion Criteria for patients * Any major systemic, psychiatric, neurological, and visual disturbance * Medical conditions or substance abuse that could interfere with cognition * Hypoacusis or severe visual deficits * Pacemaker and/or other implanted neurostimulation devices in the head/neck district * (Other) Contraindications to undergoing MRI examination * Brain damage at routine MRI, including extensive cerebrovascular disorders * Denied oral and written informed consent to study participation * Inability to repeat multisyllabic words (4 syllables) * Concomitant participation to other pharmacological and non pharmacological studies * Traumatic or surgical wounds that could determine a risk of infection in the site of non-invasive stimulation * Scalp alterations that could determine the spread of excessive current from the device. * Known history of epilepsy (due to small risk of seizure induction from rTMS in epileptic patients Inclusion criteria for healthy controls: * Sex-matched and age-matched (age range: mean age of PPA years ± 15 years) * MMSE\>27 * Native Italian Speaker * Right handedness * Oral and written informed consent to study participation Exclusion criteria for healthy controls: * Any major systemic, psychiatric, neurological, and visual disturbance * Medical conditions or substance abuse that could interfere with cognition * Hypoacusis or severe visual deficits * Pacemaker and/or other implanted neurostimulation devices in the head/neck district * (Other) Contraindications to undergoing MRI examination * Brain damage at routine MRI, including extensive cerebrovascular disorders * Denied oral and written informed consent to study participation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Primary progressive aphasia(PPA) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

primary progressive aphasia Speech

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Primary progressive aphasia(PPA)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • San Raffaele Neurotech Hub

    Milan, Milano, 20132, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.